Neurology

Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core Strengths

Softness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book…

4 months ago

Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners

For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 ScholarshipLAVAL, QC / ACCESSWIRE / August…

4 months ago

Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results

Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded…

4 months ago

Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb

Key scientific achievements drive the expansion of the pipeline of molecular glue degradersPerformance-based and programme-based payments of in total US$…

4 months ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)…

4 months ago

Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers Squibb

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress…

4 months ago

Natus introduces autoSCORE, an innovative AI solution capable of a new era of expert-level clinical EEG interpretation

MIDDLETON, Wis., Aug. 7, 2024 /PRNewswire/ -- Natus Medical Incorporated has announced the launch of autoSCORE, the first-of-its-kind artificial intelligence…

5 months ago

Evotec SE Reports First Half-year 2024 Results on 14 August 2024

HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will…

5 months ago

Applied Therapeutics Reports Second Quarter 2024 Financial Results

NDA and MAA for govorestat for treatment of Classic Galactosemia under FDA Priority Review and EMA review; PDUFA target action…

5 months ago